Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.

Saved in:
Bibliographic Details
Title: Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Authors: Lan Y; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA yan.lan@emdserono.com kinming.lo@emdserono.com., Yeung TL; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Huang H; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Wegener AA; Department of Discovery and Development Technologies, Merck Healthcare KGaA, Darmstadt, Germany., Saha S; Department of Translational Medicine, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Toister-Achituv M; Department of Discovery and Development Technologies, Merck Healthcare KGaA, Yavne, Israel., Jenkins MH; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Chiu LY; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Lazorchak A; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA.; Be Biopharma, Cambridge, Massachusetts, USA., Tarcic O; Department of Discovery and Development Technologies, Merck Healthcare KGaA, Yavne, Israel.; CAVOS Biotech, Jerusalem, Israel., Wang H; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Qi J; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Locke G; Department of Translational Medicine, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Kalimi D; Department of Discovery and Development Technologies, Merck Healthcare KGaA, Yavne, Israel., Qin G; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Marelli B; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Yu H; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Gross AW; Department of Discovery Development Technologies, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Derner MG; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Soloviev M; Department of Discovery Development Technologies, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Botte M; LeadXPro AG, Villigen, Switzerland., Sircar A; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Ma H; Department of Integrated Supply Chain Operations, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Sood VD; Department of Discovery Development Technologies, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Zhang D; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA.; D2M Biotherapeutics, Natick, Massachusetts, USA., Jiang F; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA., Lo KM; Department of TIP OIO, EMD Serono Research and Development Institute, Billerica, Massachusetts, USA yan.lan@emdserono.com kinming.lo@emdserono.com.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2021-004122